drugset / Trial / NCT04892654

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch

NCT04892654

Phase 3 Recruiting 150 enrolled Chelsea and Westminster NHS Foundation Trust
RandomizedParallel-groupOpen-labelTreatment

Summary

Combination antiretroviral therapy (cART) HIV treatments are associated with increased quality of life, and a normalisation of life expectancy in people living with HIV. However, long-term use of cART can lead to side-effects through exposure to drug-related toxicity. For this reason researchers are interested in looking at alternative therapies that might expose patients to fewer and less severe side effects while providing the same quality of care as antiretroviral therapies most often used to treat HIV. The purpose of this study is to investigate if the study drug combination that is being tested (doravirine + dolutegravir) is safe compared with other triple cART regimens.

Timeline

Start
2022-08-17
Primary completion
2026-11-30
Completion
2027-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dolutegravir Other / unclassified 50 mg Oral
Subject Doravirine Small molecule 100 mg Oral